Immunohistochemical biomarkers are prognostic relevant in addition to the ESMO-ESGO-ESTRO risk classification in endometrial cancer
Publication year
2021Source
Gynecologic Oncology, 161, 3, (2021), pp. 787-794ISSN
Publication type
Article / Letter to editor

Display more detailsDisplay less details
Organization
Gynaecology
Pathology
Radiation Oncology
Journal title
Gynecologic Oncology
Volume
vol. 161
Issue
iss. 3
Page start
p. 787
Page end
p. 794
Subject
All institutes and research themes of the Radboud University Medical Center; Radboudumc 17: Women's cancers RIHS: Radboud Institute for Health SciencesThis item appears in the following Collection(s)
- Academic publications [205116]
- Electronic publications [103350]
- Faculty of Medical Sciences [81054]
- Open Access publications [71830]
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.